COMBINED TRANYLCYPROMINE-TRIFLUOPERAZINE THERAPY IN THE TREATMENT OF PATIENTS WITH AGITATED DEPRESSIONS
Abstract
The tranylcypromine-trifluoperazine combination is of definite benefit in the treatment of patients with severe agitated depressions. In the author's experience this combination represents the only psychopharmacologic antidepressant that is of proven worth in this particular very prevalent clinical group. While others have reported that this combination has been of benefit in the treatment of chronic, regressed and withdrawn patients(4) and in chronic refractory schizophrenics(5), I have not found this to be true. To the contrary, this combination is of benefit primarily in patients with a marked increase in psychomotor activity.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
